Ningbo Linghan Enterprise Management Partnership Enterprise (Limited Partnership) entered into equity transaction contract to acquire 14.60% stake in Hangzhou Weisibo Medical Technology Co., Ltd. from Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) for CNY 8 million on December 29, 2022. As of October 26, 2022, Zhejiang Xianju Pharmaceutical directorate approved transfer of 14.60% stake in Hangzhou Weisibo Medical Technology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.16 CNY | -0.82% | -1.94% | -4.78% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.78% | 1.66B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- 002332 Stock
- News Zhejiang Xianju Pharmaceutical Co.,Ltd.
- Ningbo Linghan Enterprise Management Partnership Enterprise (Limited Partnership) entered into equity transaction contract to acquire 14.60% stake in Hangzhou Weisibo Medical Technology Co., Ltd. from Zhejiang Xianju Pharmaceutical Co.,Ltd. for CNY 8 million.